New breakthrough Alzheimer’s drug gets unanimous backing from FDA advisors
Outside advisers to the U.S. Food and Drug Administration on Monday voted unanimously that the benefits of Eli Lilly’s (LLY.N), opens new tab experimental Alzheimer’s treatment donanemab outweighed its risks, and agreed that trial data showed it was effective in patients with an early stage of the memory-robbing disease. The vote clears the way for a final … Read more